NCT04598204 is a Phase 2, PHASE3 clinical trial of Treatment with oral rapmycin in Vascular Anomalies, sponsored by Zhujiang Hospital.

Who is sponsoring NCT04598204?

NCT04598204 is sponsored by Zhujiang Hospital.

What drugs are being tested in NCT04598204?

Interventions in NCT04598204: Treatment with oral rapmycin.

What condition does NCT04598204 study?

NCT04598204 studies Vascular Anomalies.

Is NCT04598204 still recruiting?

NCT04598204 is currently status unknown. Last updated 10 November 2021.

Last reviewed 2021-11-10 · How we verify

NCT04598204

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety of Rapamycin to Complex Vascular Anomalies in Pediatric Patients

Status unknown Phase 2, PHASE3 Last updated 10 November 2021

What this trial tests

Phase 2, PHASE3 trial testing Treatment with oral rapmycin in Vascular Anomalies in 30 participants. Status unknown.

Timeline

1 December 2017

Primary endpoint
1 December 2022

1 December 2022

Quick facts

Lead sponsor	Zhujiang Hospital
Phase	Phase 2, PHASE3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	1 December 2017
Primary completion	1 December 2022
Estimated completion	1 December 2022
Sites	1 location across China

Drugs / interventions tested

Treatment with oral rapmycin — full drug profile →

Conditions studied

Vascular Anomalies — all drugs for Vascular Anomalies →

Sponsor

Zhujiang Hospital

Who can join

Adults 1 Month to 14, any sex, with Vascular Anomalies. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

KHE and TA are rare tumors and some of the cases may lead to life-threatening complications including Kasabach-Merritt Phenomenon. Typically treated with steroids and vincristine, a majority of the cases do not have good prognosis. Complex vascular malformations are always managed by surgery,sclerotherapy and embolization therapy. While many of the cases still lead to complications such as disfigurement, chronic pain, recurrent infections, coagulopathies. Different medical centers are exploring new therapy for these tough problems. This study is plotted to determine the efficacy and safety of rapamycin monotherapy in KHE/TA and complex vascular malformations in pediatric patients.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

A review of mechanisms of disease across PIK3CA-related disorders with vascular manifestations.
Canaud G, Hammill AM, Adams D, Vikkula M, et al · · 2021 · cited 122× · PMID 34238334 · DOI 10.1186/s13023-021-01929-8

Verify or expand the search:

Other recruiting trials for Vascular Anomalies

Currently open trials in the same condition.

NCT07072403 — Trametinib Treatment for Complicated Vascular Anomalies · Phase 1, PHASE2 · active not recruiting
NCT06573723 — Institutional Registry of Rare Diseases · recruiting

Other Zhujiang Hospital trials

Trials by the same sponsor.

NCT07335094 — A Clinical Study of Humanized CD19 CAR-T Cells With TLR2 for the Treatment of Adult Patients With Naive B-Cell Acute Lym · EARLY_PHASE1 · not yet recruiting
NCT07469072 — Comparison of Anticoagulant Effects of Different Doses of Nafamostat in Continuous Renal Replacement Therapy (CRRT) in t · Phase 2 · recruiting
NCT07455149 — An Observational Clinical Study on the Association of Intestinal Ruminococcus Gnavus and Its Derived Biogenic Amines Wit · not yet recruiting
NCT07457099 — Impact of Postoperative Radiotherapy Versus PD-1 Inhibitor Maintenance on Survival in Resectable Locally Advanced Oral a · not yet recruiting
NCT07454421 — Racecadotril for Organ Injury in Sepsis Patients · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04598204 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zhujiang Hospital
Last refreshed: 10 November 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04598204.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing